WIL Research Appoints David Spaight as Chief Executive Officer

Former MDS Pharma and Fisher Scientific Exec to Expand Offering, Globally

David Spaight, CEO of WIL Research Company (Photo: Business Wire)

FAIRFIELD, N.J.--()--WIL Research Company, a privately held global Contract Research Organization (CRO) and leading provider of drug development and chemical and food safety services, announced the appointment of David Spaight to the position of Chief Executive Officer and named him to their Board of Directors. Mr. Spaight will oversee the Company’s four major businesses – WIL Research Laboratories, NOTOX, Midwest BioResearch and QS Pharma – and will continue to implement a long-term strategy of integrating the businesses to provide greater value and full service to their clients, across the globe.

Mr. Spaight brings more than 25 years of experience in the life and analytical sciences industry. He has extensive experience in business integration, operational improvement and client relationship development. Most recently, he served as President of MDS Pharma Services, a leading provider of innovative drug discovery and development solutions to the pharmaceutical and biotechnology industries. He managed a team of more than 3,500 professionals across 35 sites in 27 countries. During his tenure at MDS, he served on the Board of Directors for the Association of Clinical Research Organizations (ACRO) and was named Chairman for 2008. Previously, Mr. Spaight served as Senior Vice President at Fisher Scientific Products, where he was responsible for the integration of the sales, marketing and research and development teams in North America, Europe and Asia. Prior to joining Fisher, Mr. Spaight spent 20 years with PerkinElmer Life and Analytical Sciences, rising through several management roles to the position of Vice President of Global Sales and Marketing. He received his Bachelor of Science degree in Chemistry and a Masters of Business Administration degree, both from the University of Michigan.

“Pharma companies around the world are looking for specific expertise in key areas of drug discovery and development,” said Mr. Spaight. “The scientific expertise of our staff is unmatched and provides a strong base for future growth. I look forward to strengthening this organization as we continue to deliver exceptional value to our clients.”

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6292697&lang=en

Contacts

For WIL Research Laboratories
Ken Li, 312-532-4675

Release Summary

WIL Research Laboratories named David Spaight as Chief Executive Officer and named him to their Board of Directors.

Contacts

For WIL Research Laboratories
Ken Li, 312-532-4675